HepatologyVolume 35, Issue 1 p. 235-237 EditorialFree Access Vaccination for hepatitis B after transplantation: A realistic goal? Timothy Pruett M.D., Corresponding Author Timothy Pruett M.D. [email protected] Department of Surgery, University of Virginia, Charlottesville, VADepartment of Surgery, P.O. Box 800709, University of Virginia HSC, Charlottesville, VA 22908. fax: 434-924-5539===Search for more papers by this author Timothy Pruett M.D., Corresponding Author Timothy Pruett M.D. [email protected] Department of Surgery, University of Virginia, Charlottesville, VADepartment of Surgery, P.O. Box 800709, University of Virginia HSC, Charlottesville, VA 22908. fax: 434-924-5539===Search for more papers by this author First published: 30 December 2003 https://doi.org/10.1053/jhep.2002.31024Citations: 5AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL No abstract is available for this article. References 1 Angelico M, Paolo D, Trinito M, Petrolati A, et al. Failure of a reinforced triple course of hepatitis B vacinnation in patients transplanted for HBV-related cirrhosis. Hepatology 2002; 35: 176– 181. 2 Loinaz C, de Juanes JR, Gonzalez EM, et al. Hepatitis B vaccination results in 140 liver transplant recipients. Hepatogastroenterology 1997; 44: 235– 238.MEDLINE 3 Arslan M, Wiesner RH, Sievers C, Egan K, Zein NN. Double-dose accelerated hepatitis B vaccine in patients with end-stage liver disease. Liver Transpl 2001; 7: 314– 320.MEDLINE 4 Sanchez-Fueyo A, Rimola A, Grande L, et al. Hepatitis B immunoglobulin discontinuation followed by hepatitis B virus vaccination: a new strategy in the prophylaxis of hepatitis B virus recurrence after liver transplantation. Hepatology 2000; 31: 496– 501.MEDLINE 5 Naoumov NV, Lopes AR, Burra P, et al. Randomized trial of lamivudine versus hepatitis B immunoglobulin for long-term prophylaxis of hepatitis B recurrence after liver transplantation. J Hepatol 2001; 34: 888– 894.MEDLINE 6 Dusheiko GM, Hoofnagle JH, Cooksley WG, James SP, Jones EA. Synthesis of antibodies to hepatitis B virus by cultured lymphocytes from chronic hepatitis B surface antigen carriers. J Clin Invest 1983; 71: 1104– 1113.MEDLINE 7 Barnaba V, Valesini G, Levrero M, et al. Immunoregulation of the in vitro anti-HBs antibody synthesis in chronic HBsAg carriers and in recently boosted anti-hepatitis B vaccine recipients. Clin Exp Immunol 1985; 60: 259– 266.MEDLINE 8 Kurose K, Akbar SM, Yamamoto K, Onji M. Production of antibody to hepatitis B surface antigen (anti-HBs) by murine hepatitis B virus carriers: neonatal tolerance versus antigen presentation by dendritic cells. Immunology 1997; 92: 494– 500.MEDLINE 9 Akbar SK, Horiike N, Onji M. Prognostic importance of antigen-presenting dendritic cells during vaccine therapy in a murine hepatitis B virus carrier. Immunology 1999; 96: 98– 108.MEDLINE 10 Akbar SM, Horiike N, Onji M, Hino O. Dendritic cells and chronic hepatitis virus carriers. Intervirology 2001; 44: 199– 208.MEDLINE 11 Blumberg EA, Albano C, Pruett T, et al. The immunogenicity of influenza virus vaccine in solid organ transplant recipients. Clin Infect Dis 1996; 22: 295– 302.MEDLINE 12 Soesman NM, Rimmelzwaan GF, Nieuwkoop NJ, et al. Efficacy of influenza vaccination in adult liver transplant recipients. J Med Virol 2000; 61: 85– 93.MEDLINE 13 Chow YH, Chiang BL, Lee YL, et al. Development of Th1 and Th2 populations and the nature of immune responses to hepatitis B virus DNA vaccines can be modulated by codelivery of various cytokine genes. J Immunol 1998; 160: 1320– 1329.MEDLINE 14 Oseroff C, Sette A, Wentworth P, et al. Pools of lipidated HTL-CTL constructs prime for multiple HBV and HCV CTL epitope responses. Vaccine 1998; 16: 823– 833.MEDLINE 15 Davis HL, Suparto, II, Weeratna RR, et al. CpG DNA overcomes hyporesponsiveness to hepatitis B vaccine in orangutans. Vaccine 2000; 18: 1920– 1924.MEDLINE 16 Prikazsky V, Bock HL. Higher anti-hepatitis B response with combined DTPw-HBV vaccine compared with separate administration in healthy infants at 3, 4 and 5 months of age in Slovakia. Int J Clin Pract 2001; 55: 156– 161.MEDLINE 17 Shimizu Y, Guidotti LG, Fowler P, Chisari FV. Dendritic cell immunization breaks cytotoxic T lymphocyte tolerance in hepatitis B virus transgenic mice. J Immunol 1998; 161: 4520– 4529.MEDLINE 18 Wen YM, Qu D, Zhou SH. Antigen-antibody complex as therapeutic vaccine for viral hepatitis B. Int Rev Immunol 1999; 18: 251– 258.MEDLINE 19 Schodel F, Peterson D, Milich D. Hepatitis B virus core and e antigen: immune recognition and use as a vaccine carrier moiety. Intervirology 1996; 39: 104– 110.MEDLINE Citing Literature Volume35, Issue1January 2002Pages 235-237 ReferencesRelatedInformation